<scp>U</scp>ni<scp>PR</scp>129 is a competitive small molecule <scp>E</scp>ph‐ephrin antagonist blocking <i>in vitro</i> angiogenesis at low micromolar concentrations

Abstract

The discovery of UniPR129 represents not only a major advance in potency compared with the existing Eph-ephrin antagonists but also an improvement in terms of cytotoxicity, making this molecule a useful pharmacological tool and a promising lead compound.